

National Imaging Associates, Inc.*	
Clinical guidelines BREAST MRI	Original Date: September 1997
CPT Codes: Unilateral without contrast 77046 Bilateral without contrast 77047 Unilateral without and with contrast 77048 Bilateral without and with contrast 77049, <u>+0698T</u>	Last Revised Date: <u>June-July 2021</u>
Guideline Number: NIA_CG_023	Implementation Date: January 2022

## INDICATIONS FOR BREAST MRI

(Please see boxed statements below for specific requirements for the following: [Commonwealth of Pennsylvania](#); [State of Connecticut](#); [State of North Carolina](#))

## NO HISTORY OF KNOWN BREAST CANCER

For screening examination to detect breast cancer in any of the following situations

- A Breast Cancer Risk Assessment (~~preferably using~~ including the Breast Cancer Consortium Risk Model (BCSC) which incorporates breast density, the International Breast Cancer Intervention Study (IBIS)/ Tyrer-Cuzick model ~~1 (IBIS)~~, the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA), the modified Gail (NCCN, 20192021) (also known as the Breast Cancer Risk assessment tool (BCRAT)) or ~~Tyrer-Cuzick or~~ other validated risk assessment models) that identifies the patient as having a lifetime risk of 20% or greater of developing breast cancer:
  - Approve annually beginning 10 years prior to youngest family member's age at diagnosis or at age 40, whichever comes first, but not before age 30-25 (ACR, 2018; ASBrS, 2017; Levitan, 2019; Marino, 2018; NCCN, 201921).
- Patients with lifetime risk of 20% or greater of developing breast cancer based on history of lobular neoplasia (LCIS/ALH (Lobular Carcinoma in Situ /Atypical Lobular Hyperplasia)) or ADH (atypical ductal hyperplasia).
  - Approve annually beginning at age of diagnosis of LCIS/ALH or ADH but not prior to age 25 (NCCN, 2021).
- Patients with history of extensive chest irradiation (usually as treatment for Hodgkin's or other lymphoma between ages ten and thirty)-
  - Begin ten-eight years after radiation, but not prior to age 25 (NCCN, 201821).
- Patients with known *BRCA 1/2* mutation-
  - Approve annually starting at age 25 (ASBrS, 2017; NCCN, 201921).

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- Patients not yet tested for *BRCA* gene, but with known *BRCA* mutation in first-degree relative.
  - Approve annually starting at age 25 (ASBrS, 2017; NCCN, 2019, 2021).
- Personal history of germline mutations known to predispose to a high risk of breast cancer (NCCN, 2019, 2021):
  - Li-Fraumeni syndrome (*TP53* mutation)
    - Begin age 20-29 or age at earliest diagnosed breast cancer in family
  - Cowden syndrome (*PTEN*) or Bannayan-Riley-Ruvalcaba syndrome (BRRS)
    - Begin 30-35 or 5-10 years before earliest breast cancer diagnosis in family
  - *ATM*
    - Begin age 40
  - ***BARD1***
    - **Begin age 40**
  - *CDH1*
    - Begin age 30
  - *CHEK2*
    - Begin age 40
  - *NF1*
    - Begin age 30
  - *PALB2*
    - Begin age 30
  - Peutz-Jeghers Syndrome (*STK-11*)
    - Begin age 25

**For evaluation of identified lesion, mass, or abnormality in breast in any of the following situations**

- Evaluation of suspected breast cancer when other imaging examinations, such as ultrasound and mammography, and physical examination are inconclusive for the presence of breast cancer, and biopsy could not be performed (e.g., seen only in single view mammogram without ultrasound correlation).
  - Includes skin changes of suspected inflammatory breast cancer if conventional imaging and skin biopsies are first performed and negative (ASBrS, 2017; Geiss, 2017; Yadeau, 2018).
- Inconclusive or conflicting findings on a **diagnostic screening** mammogram or ultrasound when the finding is not a palpable or a discrete mass.
- **For evaluation of suspicious mass, lesion, distortion, or abnormality of the breast in patient with history of breast cancer when other imaging is inconclusive.**
- For cases of new nipple inversion when mammographic and sonographic findings are inconclusive and a biopsy cannot be performed (Killelea, 2019).
- Patients diagnosed with biopsy-proven lobular neoplasia, i.e., **LCIS/ADH/ALH (Lobular Carcinoma in Situ atypical ductal hyperplasia/Atypical Lobular Hyperplasia)** or **LCISADH (atypical ductal hyperplasia/Lobular Carcinoma in Situ)** (ASBrS, 2017; Monticciolo, 2017; NCCN, 2021, 2019).
- Spontaneous unilateral serous or bloody nipple discharge when conventional imaging is normal and there is no palpable mass (ASBrS, 2017; Bahl, 2015; NCCN, 2019, 2021).

- Paget’s disease of the nipple: to detect underlying ductal carcinoma when conventional imaging is normal and there is no palpable mass (ASBrS, 2017).
- For a phylloides tumor diagnosed by biopsy, breast MRI may help determine extent of disease and resectability in selected cases. However routine use for surgical planning is controversial (Grau, 2019).
- Follow-up of a probably benign (BI-RADS 3) lesion seen only on prior MRI (when prior mammogram and ultrasound did not show the abnormality) (Lee, 2018; Panigrahi, 2019; Spick, 2018).

## HISTORY OF KNOWN BREAST CANCER

- Yearly surveillance for history of breast cancer and dense breast tissue on mammography (ACR, 2018).
- Yearly surveillance for individuals with personal history of breast cancer diagnosed before age 50 (ACR, 2018)
- Yearly surveillance in patients with genetic or other risk factors placing them at high risk for a new cancer or recurrence (ASBrS, 2017; Park, 2018).
- ~~To identify primary cancer in a patient with axillary nodal adenocarcinoma and unidentified primary tumor (NCCN, 2019).~~

## Staging, treatment, and surveillance of patients with a known history of Breast Cancer

- Approve for initial staging when conventional imaging is indeterminate in defining the extent of cancer, or in defining presence of multifocal, multicentric, or contralateral cancer, or if there is a discrepancy in estimated tumor size between physical exam and imaging (ASBrS, 2017; NCCN, 2021).
- For invasive lobular carcinoma that is poorly or inadequately defined by mammography, ultrasound, and/or physical exam (NCCN, 2021).
- To identify primary cancer in a patient with axillary nodal adenocarcinoma and unidentified primary tumor (NCCN, 2021).
- Prior to treatment: To serve as a baseline for comparison prior to a patient starting planned neoadjuvant chemotherapy (ACR, 2017).
- During or after treatment: To identify candidates for breast conserving therapy or evaluate response to treatment, including preoperative neoadjuvant therapy [within three (3) months] (ASBrS, 2017).
  - ~~Yearly surveillance in patients with genetic or other risk factors placing them at high risk for a new cancer or recurrence (ASBrS, 2017; Park, 2018).~~

## ~~For evaluation of identified lesion, mass, or abnormality in breast in any of the following situations~~

- ~~For evaluation of breast lesion, identifying whether single or multi focal, in patient with newly diagnosed breast cancer (ASBrS, 2017; NCCN, 2018).~~
- ~~For evaluation of suspicious mass, lesion, distortion, or abnormality of breast in patient with history of breast cancer when other imaging is inconclusive.~~

## Silicone Implants

MRI is not indicated for evaluation of saline implant complications or for asymptomatic silicone implants.

(ACR, 2018; Lawrence, 2018)

- Confirmation of suspected silicone gel-filled breast implant ruptures in *asymptomatic* patients, after an abnormal or indeterminate finding on mammography or breast ultrasound-
- MRI is considered the gold standard for evaluation of symptomatic silicone implant rupture (ACR, 2018; ASBrS, 2017). **Prior imaging is not required in patients with silicone implants and symptoms of possible rupture.**
- For postoperative evaluation of silicone breast implant complications when other imaging is inconclusive-

## Pre-operative

- For preoperative evaluation for known breast cancer when surgery planned within thirty (30) days to be determined on a case-by-case basis (ASBrS, 2017; NCCN, 2019; Susnik, 2018; Wong, 2018)-

## Post-operative/procedural evaluation

- A follow-up study may be needed to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed for the type and area(s) requested (ACR, 2018)-

### \*\*\*FOR STATE OF CONNECTICUT ONLY\*\*\*

CT ST § 38a-530

Effective: October 1, 2020

Coverage for breast MRI is mandated within the State of Connecticut without coinsurance, copay of more than \$20 deductible, or other out of pocket expenses for women with dense breast tissue if the woman is believed to be at increased risk of breast cancer because of family or personal history of breast cancer, positive genetic testing. Coverage is also mandated for other indications determined by a woman's physician, or when screening is recommended by a physician and the woman is over age 40, has a family or prior history of breast cancer or has breast disease diagnosed through biopsy as benign. This applies to high deductible plans unless plans are used to establish an HRA or HSA to the extent permitted by federal law. Though not designated in the original intent of the bill, language includes the above provisions and criteria for breast MRI.

Source: Connecticut General Assembly

[https://www.cga.ct.gov/current/pub/chap\\_700c.htm](https://www.cga.ct.gov/current/pub/chap_700c.htm)

\*\*\*FOR STATE OF NORTH CAROLINA ONLY\*\*\*

Medicaid and NCHC cover magnetic resonance imaging (MRI) for the detection of:

1. Breast cancer in beneficiaries who are at a high genetic risk for breast cancer:
  - A. known BRCA 1 or 2 mutation in beneficiary;
  - B. known BRCA 1 or 2 mutation in relatives; or
  - C. pattern of breast cancer history in multiple first-degree relatives, often at a young age and bilaterally.
2. Breast cancer in beneficiaries who have breast characteristics limiting the sensitivity of mammography (such as dense breasts, implants, scarring after treatment for breast cancer).
3. A suspected occult breast primary tumor in beneficiaries with axillary nodal adenocarcinoma with negative mammography and clinical breast exam.
4. Breast cancer in beneficiaries with a new diagnosis of breast cancer. It can be used to determine the extent of the known cancer and/or to detect disease in the contralateral breast.
5. To evaluate implant integrity in beneficiaries with breast implants.

**Source:** NC Medicaid, Amended March 15, 2019

[https://files.nc.gov/ncdma/documents/files/1K-1\\_2.pdf](https://files.nc.gov/ncdma/documents/files/1K-1_2.pdf)

**\*\*\*FOR THE COMMONWEALTH OF PENNSYLVANIA ONLY\*\*\***

**40 P.S. § 764c**

**Act of Jul. 1, 2020, P.L. 572, No. 52 (SB 595)**

- I. Plans that provide hospital or medical/surgical coverage shall also provide coverage for breast imaging.
- II. The minimum coverage required shall include:
  1. Supplemental magnetic resonance imaging or, if such imaging is not possible, ultrasound
  2. If recommended by the treating physician because the woman is believed to be at an increased risk of breast cancer due to:
    - a. personal history of atypical breast histologies;
    - b. personal history or family history of breast cancer;
    - c. genetic predisposition for breast cancer;
    - d. prior therapeutic thoracic radiation therapy;
    - e. heterogeneously dense breast tissue based on breast composition categories of the Breast Imaging and Reporting Data System established by the American College of Radiology with any one of the following risk factors:
      - i. lifetime risk of breast cancer of greater than 20%, according to risk assessment tools based on family history;
      - ii. personal history of BRCA1 or BRCA2 gene mutations;
      - iii. first-degree relative with a BRCA1 or BRCA2 gene mutation but not having had genetic testing herself;
      - iv. prior therapeutic thoracic radiation therapy between 10 and 30 years of age; or
      - v. personal history of Li-Fraumeni syndrome, Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome or a first-degree relative with one of these syndromes;
      - vi. extremely dense breast tissue based on breast composition categories of the Breast Imaging and Reporting Data System established by the American College of Radiology.

Nothing in this subsection shall be construed to require an insurer to cover the surgical procedure known as mastectomy or to prevent the application of deductible, copayment or coinsurance provisions contained in the policy or plan.

Source: Senate Bill 595 @

<https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2020&sessInd=0&act=52>

## BACKGROUND

Magnetic resonance imaging (MRI) of the breast is a useful tool for the detection and characterization of breast disease, assessment of local extent of disease, evaluation of treatment response, and guidance for biopsy and localization (Panourgias, 2018). Breast MRI should always be bilateral to allow for assessment of symmetry between the breasts ~~except for those with a history of mastectomy or when the MRI is being performed expressly to further evaluate or follow findings in one breast~~. MRI

findings should be correlated with clinical history, physical examination, and the results of mammography and any other prior breast imaging.

## OVERVIEW

**Staging of newly diagnosed breast cancer** – The decision to use breast MRI as an adjunct to clinical exam, mammography, and ultrasound should be made by the physician on a case-by-case basis, taking into account frequent false positives, increased time to treatment, and increased mastectomy rates. “There is no convincing evidence that MRI reduces re-excision Lumpectomy rates, local recurrence, or overall survival in patients with invasive breast cancer or ductal carcinoma in situ” (ASBrS, 2017; NCCN, 2021).

## **MRI AND RISK EVALUATION and risk evaluation –**

**The age of a family member’s diagnosis is only relevant for patients under the age of 40. Anyone 40 or over should be getting annual mammograms and breast MRIs if their lifetime risk is 20% or greater.**

**MRI and dense breasts** – Women with extremely dense breasts are 4-6x more likely to develop breast cancer than women with fatty tissue. Between 40 - 50% of US women aged 40-74 years have dense breast tissue. Breast density decreases the sensitivity of mammography and is associated with aggressive tumors and worse outcomes. ~~A movement to notify women of their breast density is now expanded, as of April 2019 to 38 states and the District of Columbia. Although there has been an increase in notification and awareness of breast density, no clear guidelines have been established for supplemental screening in this subset of women. A recent study showed that the majority of practices are utilizing supplemental screening, but the modalities used and referral patterns are variable depending on several factors including location, type of practice i.e., private or academic, and whether the practice has breast specialists. Also, the exact notification requirements vary as well as insurance coverage from state to state. Screening ultrasound was most utilized (53%) and most available in the Northeast (80%). Connecticut requires insurance to cover supplemental ultrasound exams. In this study 19.5% had MRI for supplemental screening and 87% of these were private practice settings (Choudhery, 2020).~~

There are four categories for breast density- almost entirely fatty, scattered areas of fibroglandular tissue, heterogeneously dense, and extremely dense. The last two are considered dense. Women with dense breasts and a BCSC risk of  $\geq 2.5\%$  (about 21%) are at greatest risk for interval stage IIb or higher cancers. Thus, knowing a women’s risk along with density identifies subgroups who will benefit most from supplemental testing, such as ultrasound or MRI. Without considering overall breast cancer risk, MRI could result in more harm than good in terms of anxiety, overdiagnosis, and increased benign breast biopsies. (KerlikowskiKerlikowske, 2019). For women whose only risk is increased breast density, ultrasound can be considered for adjunctive screening (Monticciolo, 2018).

**A movement to notify women of their breast density is now expanded, as of April 2019, to 38 states and the District of Columbia. Although there has been an increase in notification and awareness of breast density, no clear guidelines have been established for supplemental screening in this subset of women. A recent study showed that the majority of practices are utilizing supplemental**

screening, but the modalities used and referral patterns vary depending on several factors including location, type of practice (i.e., private or academic), and whether the practice has breast specialists. Also, the exact notification requirements as well as insurance coverage vary from state to state. Screening ultrasound was most utilized (53%) and most available in the Northeast (80%). Connecticut, for example, requires insurance to cover supplemental ultrasound exams. In this study 19.5% had MRI for supplemental screening and 87% of these were private practice settings (Choudhery, 2020). At the present time, except in states that require it, more research is needed before approval of MRI for supplemental screening based on breast density alone, without other risk factors (Bakker, 2019; Destounis, 2020; Kerlikowski, 2019).

#### **MRI and Breast Cancer Risk Associated with certain Syndromes**

- Lynch Syndrome- Women with Lynch syndrome and mismatch repair genes *MLH1* and *MSH2* may be at increased risk for breast cancer; however, breast screening is not recommended beyond what is recommended for an average risk patient (NCCN, 2021).

- NF-1- Mammography starting at age 30; breast MRI may be considered.

There is currently ~~limited~~ evidence that *RAD51C* and *RAD51D* genes are associated with increased risk of breast cancer. Insufficient evidence for *FANCC*, *MRE11A*, or *MUTYH* heterozygotes, or *RECQL4*, *RAD50*, *RINT1*, *SLX4*, *SMARCA4*, or *XRCC2*. For *STK11* (associated with Peutz-Jeghers syndrome) breast cancer risk is 8% at age 40, 13% age 50, and 31% at age 60, and 45% age 70.

~~Abbreviated Breast MRI – Among women with dense breasts undergoing screening, this technique, compared with digital breast tomosynthesis, was associated with significantly higher rate of detection of invasive cancer and further research is needed. A clinical trial is now underway (ClinicalTrials.gov:NCT02933489). A total acquisition time of 10 minutes is needed to image the breasts (Comstock, 2020).~~

**Surgical excision vs MRI** – Select patients may be suitable for monitoring in lieu of excision (although MRI is not indicated); e.g., Flat epithelial hyperplasia, papillomas without atypia, fibroepithelial lesions favoring fibroadenoma, radial scars adequately sampled or incidental. Other pathologies that may require excision include mucin-producing lesions, potential phylloides tumor, papillary lesions, radial scar, or other histologies of concern to the pathologist (NCCN, 2021).

**MRI during or after Neoadjuvant Chemotherapy** – Dynamic contrast-enhanced MRI may be used to monitor response of a tumor to neoadjuvant chemotherapy used to shrink the tumor before surgery. This is very important in clinical decision making as alternative therapies may be selected based upon the MRI results obtained from the MRI. It may also be used to depict residual disease after neoadjuvant chemotherapy. MRI-compatible localization tissue markers should be placed prior to neoadjuvant chemotherapy to evaluate the location of the tumor in the event of complete response (ACR, 2018).

**MRI and Breast Implants** – For asymptomatic women with silicone implants, no imaging is recommended for evaluation. However, MRI may be used in asymptomatic patients with silicone



breast implants to evaluate breast implant integrity when a mammogram and/or ultrasound is suspicious for implant rupture.

For evaluation of unexplained axillary adenopathy in a patient under age 30, ultrasound (US) of the axilla is the recommended initial test. For age over 30, a mammogram and/or US of the axilla are recommended.

**MRI after mastectomy**—Most breast tissue is removed after mastectomy; however, recurrence may occur in residual tissue. The majority occur in the skin, subcutaneous tissues or deep to the pectoralis muscle and are reported to be about 1-2% annually. Clinical evaluation is the mainstay of the ~~post~~ **post**-mastectomy breast. For a palpable lump or pain on the side of mastectomy with or without reconstruction or a high-risk patient ~~post-post~~ bilateral prophylactic mastectomy with reconstructions, MRI is not indicated. There is no relevant literature to support MRI to screen the ~~post-post~~ mastectomy breast (although may be indicated for contralateral native breast based on breast cancer risk). MRI may be useful for a palpable lump to help characterize malignancy once identified by ultrasound. Note that tissue expanders may be a contraindication to MRI (ACR, 2020).

**Breast pain**—Breast pain is a common complaint with the incidence of breast cancer with breast pain as the only symptom, 0-3%. Clinically insignificant breast pain is cyclical, non-focal, or diffuse. There is no relevant literature regarding the use of MRI for focal or non-cyclical breast pain at any age (ACR, 2018).

**MRI for a mass**—“Any highly suspicious breast mass detected by imaging should be biopsied, irrespective of palpable findings; and any suspicious breast mass detected by palpation should be biopsied, irrespective of imaging findings” (ACR, 2016).

**MRI and ~~known~~ **known** ~~Breast~~ **Breast** ~~Cancer~~ **Cancer****—“The ASBrS does not recommend routine diagnostic MRI in newly diagnosed breast cancer patients except as part of a scientific study... Routine annual MRI is not indicated for screening of women with a prior history of breast cancer unless they have a known genetic or other significant risk factor placing them at high-risk for a new breast cancer ...” (ASBrS, 2017). Clinical indications and applications per NCCN state that Breast MRI may be used for staging evaluation to define extent of cancer or presence of multifocal or multicentric disease in the ipsilateral breast, or as screening of the contralateral breast at time of initial diagnosis (Category 2B); however, there are no high level data to demonstrate that the use of MRI to facilitate local therapy decision-making improves local recurrence or survival. False positive findings are common and surgical decisions should not be based solely on MRI, tissue sampling of areas of concern recommended (NCCN, ~~2019~~ **2021**).

**MRI and breast cancer in men**—Breast MRI is generally not indicated for palpable masses or axillary adenopathy prior to biopsy. Studies are limited as to the diagnostic accuracy or clinical usefulness of MRI in male patients (ACR, 2018).

**Nipple dDischarge** — Nipple discharge is a common complaint with at least 80% of women having at least 1 episode. Discharge that is considered pathologic is unilateral, spontaneous, from one duct orifice and serous or bloody. Physiologic discharge will be bilateral, from multiple ducts, and white, green, or yellow in color. “In general, MRI should be considered in cases in which other approaches have failed to identify an underlying cause of pathologic nipple discharge. The sensitivities of breast MRI for detection of underlying cause of pathologic nipple discharge are 86% to 100% for invasive cancer and 40% to 100% for noninvasive disease” (ACR, 2016). Ductography (galactography) has the ability to demonstrate very small lesions in the specific duct that is secreting the pathologic nipple discharge. However, it is invasive and may cause discomfort and pain. It can be time-consuming and technically challenging and the rate of incomplete ductography is as high as 15%. The discharge must be present on the day of the study so that a cannula can be placed in the appropriate duct. Failure to cannulate the discharging duct may occur and cannulation of the wrong duct may cause a false-negative ductogram (ACR, 2016).

**BI-RADS 3 (Probably Benign) MRI and Follow-up** — A follow-up MRI study may be indicated to confirm stability of a probably benign mass seen only on prior MRI. In a review of sixteen studies of high-risk patients, the frequency of MRI examinations reported as BI-RADS 3 was between 6 and 12% (Lee, 2018). In an average risk screening population of 2120 women and 3,861 MRI exams, 4.9% of MRI exams were BI-RADS 3 (Kuhl, 2017). Specific features of what constitutes a BI-RADS 3 lesion were not described in these studies, is at the discretion of the reporting radiologist, and ~~the definition was still~~ had an evolving definition during the study periods. At this writing the appropriate use of BI-RADS 3 for breast MRI has not been fully defined (Panigrahi, 2019). “The most appropriate and common use of BI-RADS 3 assessment is for a round- or oval-shaped mass with circumscribed margins and hyperintense T2 signal, which has either homogeneous enhancement or dark internal septations on a baseline examination. A mass meeting these criteria is most likely an intramammary lymph node or fibroadenoma” (Lee, 2018). The reported malignancy rate is ≤ 2% for lesions classified as BI-RADS 3 (Lee, 2018; Spick, 2018).

## POLICY HISTORY

Date	Summary
<del>June</del> <u>July</u> 2021	<p><u><del>Review Date: July 2021</del></u></p> <ul style="list-style-type: none"> <li>• <u>Improved section on when to begin high risk screening for patients with lifetime risk of 20% or greater.</u></li> <li>• <u>Added section on high risk screening in patients with lifetime risk of 20% or greater based on history of LCIS/ALH/ADH.</u></li> <li>• <u>Changed high risk screening start date to 8 years after chest irradiation per NCCN</u></li> <li>• <u>Added BARD1 germline mutation</u></li> <li>• <u>Improved section on when MRI may be indicated for a new diagnosis of breast cancer</u></li> <li>• <u>Added indication of baseline MRI prior to starting neoadjuvant chemotherapy</u></li> </ul>

	<ul style="list-style-type: none"> <li>• <u>Improvement background section on MRI of the breast</u></li> <li>• <u>Updated background section on genetic syndromes</u></li> <li>• <u>Removed background section on abbreviated breast MRI</u></li> </ul>
<u>February 2021</u>	<ul style="list-style-type: none"> <li>• <u>Added state specific language box for State of Pennsylvania</u></li> <li>• <u>Added citations to state specific boxes</u></li> </ul>
<u>May 2020</u>	<ul style="list-style-type: none"> <li>• <u>Added not indicated for saline implants, or asymptomatic silicone without prior imaging</u></li> <li>• <u>Added gold standard for symptomatic silicone implant rupture</u></li> <li>• <u>Removed section on increased breast density</u></li> <li>• <u>Improved section on breast assessment tools</u></li> <li>• <u>Improved section on germline mutations from NCCN 2019</u></li> <li>• <u>Added indication of new nipple inversion</u></li> <li>• <u>Added phylloides</u></li> <li>• <u>Added ACR for known breast cancer surveillance with dense tissue or dx &lt; age 50</u></li> <li>• <u>Added comment section on MR for dense breast, syndromes, implants, after mastectomy, breast pain, cancer in male</u></li> </ul>
<u>September 2019</u>	<ul style="list-style-type: none"> <li>• <u>Added state specific language boxes for State of Connecticut and State of North Carolina</u></li> </ul>
<u>April 2019</u>	<ul style="list-style-type: none"> <li>• <u>For silicone implants indication, added qualifying terms to assure patient is symptomatic and other imaging is inconclusive</u></li> <li>• <u>For ‘No history of breast cancer, screening examinations’ added specifics about when the screening should be done</u></li> <li>• <u>Removed indication “Two or more first degree relatives (parents, siblings, and children) have history of breast cancer”</u></li> <li>• <u>Provided specifics on chest radiation including when to start screening: “Patients with histories of extensive chest irradiation (usually as treatment for Hodgkin’s or other lymphoma between ages ten and thirty. Begin ten years after radiation, but not prior to age 25”</u></li> <li>• <u>For indication: “Personal history of germline mutations”, removed ‘or first degree relative with’ and added some of the different mutations and when screening should begin</u></li> <li>• <u>For indication: “For evaluation of identified lesion, mass, or abnormality in breast in any of the following situations”, removed “Two or more first degree relatives with history of breast cancer”</u></li> <li>• <u>For “Evaluation of breast cancer when other imaging exams are inconclusive” added “includes skin changes of suspected inflammatory breast cancer”</u></li> </ul>

- Expanded the suspicious precursor lesions to include “atypical lobular hyperplasia and lobular carcinoma in situ”
- Added indications: “Spontaneous unilateral serous or bloody nipple discharge when conventional imaging is normal and there is no palpable mass” AND “Paget’s disease of the nipple: to detect underlying ductal carcinoma when conventional imaging is normal and there is no palpable mass”
- Added indication: “Follow-up of a BI-RAD 3 lesion seen only on prior MRI when prior mammogram and US did not show the abnormality”
- History of Known Breast Cancer: Changed subheading from “Screening exam to detect breast cancer” to “Staging, treatment, and surveillance of patients with a known history of breast cancer” AND added specific indications including:
  - Approve initial staging when conventional imaging is indeterminate in defining multifocal, multicentric, contralateral cancer or there is a discrepancy in estimated tumor size between physical exam and imaging
  - During or after treatment to identify candidates for breast conserving therapy or evaluate response to treatment, including preoperative neoadjuvant therapy [within three (3) months]
  - Yearly surveillance in patients with genetic or other risk factors placing them at high risk for a new cancer or recurrence”
- For evaluation of suspicious mass, lesion, distortion, or abnormality of breast in patient with history of breast cancer: added - ‘when other imaging is inconclusive’
- Added Background information on Nipple Discharge and specifics on screening for newly diagnosed or patients with breast cancer history
- Updated references

**Review Date:** April 2019

**Review Summary:**

- ~~For silicone implants indication, added qualifying terms to assure patient is symptomatic and other imaging is inconclusive~~
- ~~For ‘No history of breast cancer, screening examinations’ added specifics about when the screening should be done~~
- ~~Removed indication “Two or more first degree relatives (parents, siblings, and children) have history of breast cancer”~~

- ~~Provided specifics on chest radiation including when to start screening: “Patients with histories of extensive chest irradiation (usually as treatment for Hodgkin’s or other lymphoma between ages ten and thirty. Begin ten years after radiation, but not prior to age 25”~~
- ~~For indication: “Personal history of germline mutations”, removed ‘or first degree relative with’ and added some of the different mutations and when screening should begin~~
- ~~For indication: “For evaluation of identified lesion, mass, or abnormality in breast in any of the following situations”, removed “Two or more first degree relatives with history of breast cancer”~~
- ~~For “Evaluation of breast cancer when other imaging exams are inconclusive” added “includes skin changes of suspected inflammatory breast cancer”~~
- ~~Expanded the suspicious precursor lesions to include “atypical lobular hyperplasia and lobular carcinoma in situ”~~
- ~~Added indications: “Spontaneous unilateral serous or bloody nipple discharge when conventional imaging is normal and there is no palpable mass” AND “Paget’s disease of the nipple: to detect underlying ductal carcinoma when conventional imaging is normal and there is no palpable mass”~~
- ~~Added indication: “Follow up of a BI-RAD 3 lesion seen only on prior MRI when prior mammogram and US did not show the abnormality”~~
- ~~History of Known Breast Cancer: Changed subheading from “Screening exam to detect breast cancer” to “Staging, treatment, and surveillance of patients with a known history of breast cancer” AND added specific indications including:~~
  - ~~Approve initial staging when conventional imaging is indeterminate in defining multifocal, multicentric, contralateral cancer or there is a discrepancy in estimated tumor size between physical exam and imaging~~
  - ~~During or after treatment to identify candidates for breast conserving therapy or evaluate response to treatment, including preoperative neoadjuvant therapy [within three (3) months]~~
  - ~~Yearly surveillance in patients with genetic or other risk factors placing them at high risk for a new cancer or recurrence”~~
- ~~For evaluation of suspicious mass, lesion, distortion, or abnormality of breast in patient with history of breast cancer: added ‘when other imaging is inconclusive’~~
- ~~Added Background information on Nipple Discharge and specifics on screening for newly diagnosed or patients with breast cancer history~~
- ~~Updated references~~

#### **POLICY HISTORY:**

**Review Date:** September 2019

#### **Review Summary:**

- ~~Added state specific language boxes for State of Connecticut and State of North Carolina~~

**Review Date:** May 2020

**Review Summary:**

- ~~Added not indicated for saline implants, or asymptomatic silicone without prior imaging~~
- ~~Added gold standard for symptomatic silicone implant rupture~~
- ~~Removed section on increased breast density~~
- ~~Improved section on breast assessment tools~~
- ~~Improved section on germline mutations from NCCN 2019~~
- ~~Added indication of new nipple inversion~~
- ~~Added phylloides~~
- ~~Added ACR for known breast cancer surveillance with dense tissue or dx < age 50~~
- ~~Added comment section on MR for dense breast, syndromes, implants, after mastectomy, breast pain, cancer in male~~

**Review Date:** February 2021

**Review Summary:**

- ~~Added state specific language box for State of Pennsylvania~~
- ~~Added citations to state specific boxes~~

**Review Date:** July 2021

- ~~Improved section on when to begin high risk screening for patients with lifetime risk of 20% or greater.~~
- ~~Added section on high risk screening in patients with lifetime risk of 20% or greater based on history of LCIS/ALH/ADH.~~
- ~~Changed high risk screening start date to 8 years after chest irradiation per NCCN~~
- ~~Added BARD1 germline mutation~~
- ~~Improved section on when MRI may be indicated for a new diagnosis of breast cancer~~
- ~~Added indication of baseline MRI prior to starting neoadjuvant chemotherapy~~
- ~~Improvement background section on MRI of the breast~~
- ~~Updated background section on genetic syndromes~~
- ~~Removed background section on abbreviated breast MRI~~

## REFERENCES

Ahn S, Elnekaveh B, et Al. Defining the Need for Imaging and Biopsy after Mastectomy. *Ann Surg Oncol*. 2018; 25:3843-3848.

American Cancer Society (ACS). Breast MRI for the early detection of breast cancer. *American Cancer Society*. March 2014.

<http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-ac-recs>.

American College of Radiology (ACR). ACR Appropriateness Criteria® - Evaluation of Nipple Discharge. 2016.

American College of Radiology (ACR). ACR Appropriateness Criteria® Imaging after Mastectomy and Breast Reconstruction. 2020.

**American College of Radiology (ACR). ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. 2017.**

American College of Radiology (ACR). ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. ACR Appropriateness Criteria; resolution 34: 2018. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-breast.pdf>. Accessed November 8, 2018.

American Society of Breast Surgeons (ASBrS). Consensus Guideline on diagnostic and screening magnetic resonance imaging of the breast. June 22, 2017. [https://www.breastsurgeons.org/about/statements/PDF\\_Statements/MRI.pdf](https://www.breastsurgeons.org/about/statements/PDF_Statements/MRI.pdf). Accessed November 26, 2018.

Ashfaq A, Senior D, Pockaj BA, et al. Validation study of a modern treatment algorithm for nipple discharge. *Am J Surg*. 2014; 208(2):222-7.

Bahl M, Baker JA, Greenup RA, et al. Evaluation of pathologic nipple discharge: What is the added diagnostic value of MRI? *Ann Surg Oncol*. 2015; 22 Suppl 3:S435-41.

Bakker MF, deLange SV, et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. *NEJM*. 2019; 381(22).

Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. *JAMA*. 2012; 307(13):1394-1404.

Brennan ME, McKessar M, Snook K, et al. Impact of selective use of breast MRI on surgical decision-making in women with newly diagnosed operable breast cancer. *Breast*. 2017; 32:135-143.

Bruening W, Uhl S, Fontanarosa J, et al. Noninvasive diagnostic tests for breast abnormalities: Update of a 2006 review. *Agency for Healthcare Research and Quality*. Rockville: MD; 2012; CER47. <http://www.ncbi.nlm.nih.gov/books/NBK84530/>.

**Choudhery S, Patel BK, Johnson M, et al. Trends of supplemental screening in women with dense breasts. *J Am Coll Radiol*. 2020;17(8):990-998. doi:10.1016/j.jacr.2019.12.031.**

~~Choudhery S, Bhavika K, et al. Trends of Supplemental Screening in Women with Dense Breasts. *J Am Coll Radiol*. 2020; Article in Press.~~

Comstock CE, Gatsonis C, et al. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women with Dense Breasts Undergoing Screening. *JAMA*. 2020; 323(8):746-756.

Connecticut General Assembly - § 38a-530. Mandatory coverage for mammography, breast ultrasound and magnetic resonance imaging. Breast density information included in mammography report. Effective October 1, 2020. [https://www.cga.ct.gov/current/pub/chap\\_700c.htm](https://www.cga.ct.gov/current/pub/chap_700c.htm).

Destounis SV, Santacroce A, et al. Update on Breast Density, Risk Estimation, and Supplemental Screening. *AJR*. 2020; 214.

Elsamaloty H, Elzawawi MS, Mohammad S, et al. Increasing accuracy of detection of breast cancer with 3-T MRI. *AJR Am J Roentgenol*. 2009; 192:1142-1148.

Förnvik D, Kataoka M, Lima M, et al. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. *Eur Radiol*. 2018; 28(8):3194-3203.

Geiss CS, Chikarmane SA, Dorothy A Sippo DA, et al. Clinical utility of breast MRI in the diagnosis of malignancy after inconclusive or equivocal mammographic diagnostic evaluation. *AJR Am J Roentgenol*. 2017; 208:1378-1385.

Godinez J, Gombos EC, Chikarmane SA, et al. Breast MRI in the evaluation of eligibility for accelerated partial breast irradiation. *American Journal of Roentgenology*. 2008; 191(1): 272-277.

Grau AM, Chakravarthy AB, Chugh R, et al. Phylloides Tumor of the breast. Up to Date. January 2020.

Grobmyer SR, Mortellaro VE, Marshall J, et al. Is there a role for routine use of MRI in selection of patients for breast-conserving cancer therapy? *J Am Coll Surg*. 2008; 206(5):1045.

Guindalini RS, Zheng Y, Abe H, et al. Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. *Clin Cancer Res*. 2018; pii:0200.2018.



Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast--risk assessment and management options. *N Engl J Med*. 2015; 372(1):78-89.

Harvey JA, Mahoney MC, Newell MS, et al. ACR Appropriateness criteria palpable breast masses. *J Am Coll Radiol*. 2016; 13(11S):e31-e42.

Houssami N, Ciattyo S, Martinelli F, et al. Early detection of second breast cancers improves prognosis in breast cancer survivors. *Ann Oncol*. 2009; 20(9):1505-1510.

Insurance Company Law of 1921 – Coverage for Mammographic Examinations, Act of July 1, 2020, P.L. 572, No. 52 (SB 595). Accessed February 15, 2021.  
<https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2020&sessInd=0&act=52>.

Kerlikowski K, Miglioretti DL, et al. Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019. *JAMA*. 2019; 322(1):69-70.

Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology*. 2013; 31(7):961-965.

Killelea B, Sowden M. Nipple Inversion. *Up to Date*. Jan 28, 2019.

Kuhl CK, Strobel K, Bieling H, et al. Supplemental breast MRI screening of women with average risk of breast cancer. *Radiology*. 2017; 283(2):361-370.

Lam DL, Houssami N, Lee JM. Imaging surveillance after primary breast cancer treatment. *AJR Am J Roentgenol*. 2017; 208(3):676-686.

Lee DH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. *JACR*. 2010; 7(1):18–27.

Lee KA, Talati N, Oudsema R, et al. BI-RADS 3: Current and future use of probably benign. *Curr Radiol Rep*. 2018; 6(2):5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787219/>.

Lehman CD, Lee AY, Lee CI. Imaging management of palpable breast abnormalities. *AJR Am J Roentgenol*. 2014; 203(5):1142-53.

Lepori D. Inflammatory breast disease: The radiologist's role. *Diagn Interv Imaging*. 2015 Oct; 96(10):1045-64.

Levitan DE. Which Breast Cancer Risk Models are Most Accurate? *Breast Cancer News*. February 27, 2019

Lourenco AP, Moy L, Baron P, et al. ACR Appropriateness criteria® - Breast implant evaluation. *J Am Coll Radiol*. 2018; 15(5S):S13-S25.

Mainiero MB, Lourenco A, Mahoney MC, et al. ACR Appropriateness criteria breast cancer screening. *J Am Coll Radiol*. 2016; 13(11S):R45-R49.

Mandelblatt JS, Stout NK, Schechter CB, et al. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. *Ann Intern Med*. 2016; 164(4):215-25.

Mann RM, Hooegeveen YL, Blickman JG, et al. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: A review of existing literature. *Breast Cancer Res Treat*. 2008;107:1-14.

Marino MA, Riedl CC, Bernathova M, et al. Imaging phenotypes in women at high risk for breast cancer on mammography, ultrasound, and magnetic resonance imaging using the Fifth Edition of the Breast Imaging Reporting and Data System. *Eur J Radiol*. 2018; 106:150-159.

McLaughlin, SA. Current controversies surrounding MRI screening for breast cancer. *Am J Hematol Oncol*. 2015; 11(8).

Miller JC, Rafferty EA, Specht MC, et al. When is breast magnetic resonance imaging recommended for cancer detection? *J Am Coll Radiol*. 2008; 5(3): 224-226.

Monticciolo DL, Newell MS, et al. Breast Cancer Screening in Women at Higher-than-Average Risk: Recommendations from the ACR. *JACR*. 2018 Mar; 15(3):408-414.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) Breast Cancer Version 6.2021. Published August 16, 2021. Accessed August 19, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf).

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) Breast Cancer Screening and Diagnosis Version 1.2021. Published May 6, 2021. Accessed August 19, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast-screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf).

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis v.1.2021.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v.3.2018. Fort Washington, PA. 2018.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v.5.2021.

**National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic v.2.2021.**

North Carolina (NC) Medicaid. Breast Imaging Procedures. Medicaid and Health Choice Clinical Coverage Policy No: 1K-1. Amended March 15, 2019. [https://files.nc.gov/ncdma/documents/files/1K-1\\_2.pdf](https://files.nc.gov/ncdma/documents/files/1K-1_2.pdf).

Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 Guideline update from the American Cancer Society. *JAMA*. 2015; 314(15):1599-614.

Panigrahi B, Harvey, SC, Mullen LA, et.al. Characteristics and outcomes of BI-RADS 3 lesions on Breast MRI. 2019 Feb; 19(1):e152-9.

Panourgias E, Bourgioti C, Koureas A, et al. MR imaging features and tumor biomarkers of screen-detected and non-screen detected breast cancers: preliminary results of a comparative study. *Clin Imaging*. 2018; 52:350-355.

Park VY, Kim EK, Kim MJ, et al. Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging. *BMC Cancer*. 2018; 18(1):91.

Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin*. 2017; 67(2):100-121.

Spick C, Bickel H, Polanec SH, et al. Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: A systematic review and meta-analysis. *Eur Radiol*. 2018; 28(5):1919–28.

Susnik B, Schneider L, Swenson KK, et al. Predictive value of breast magnetic resonance imaging in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer? *J Surg Oncol*. 2018; 118(1):221-227.

Wong SM, Prakash I, Trabulsi N, et al. Evaluating the impact of breast density on preoperative MRI in invasive lobular carcinoma. *J Am Coll Surg*. 2018; 226(5):925-932.

Yadav P, Chauhan S. Effectivity of combined diffusion-weighted imaging and contrast-enhanced MRI in malignant and benign breast lesions. *Pol J Radiol*. 2018; 83:e82-e93.

Yu J, Park A, Morris E, et al. MRI screening in a clinic population with a family history of breast cancer. *Ann Surg Oncol*. 2008; 15(2):452-461.

Zhou P, Wei Y, Chen G, et al. Axillary lymph node metastasis detection by magnetic resonance imaging in patients with breast cancer: A meta-analysis. *Thorac Cancer*. 2018; 9(8):989-996.

**Reviewed / Approved by NIA Clinical Guideline Committee**

## **GENERAL INFORMATION**

**It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.**

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.